Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres

Vox Sanguinis

Volumn 112, Issue 1, 2017, Pages 9-17

  van der Meer, P F ^a,b   Couture, C ^c   Hervig, T ^d   Kruit, G ^a   Devine, D V ^c   de Korte, D ^a   Kerkhoffs, J L ^b,e  

^a CENTRAL LABORATORY   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c CANADIAN BLOOD SERVICES   (Canada)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e HAGA HOSPITAL   (Netherlands)

Author keywords

blood component production; blood components; blood processing; platelet components; platelet concentrates

Indexed keywords

RIBOFLAVIN; THROMBOCYTE CONCENTRATE;

ARTICLE; BLOOD SAMPLING; HUMAN; IN VITRO STUDY; LIGHT EXPOSURE; PATHOGEN REDUCTION SYSTEM; PLASMA; PRIORITY JOURNAL; ROOM TEMPERATURE; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; ULTRAVIOLET B RADIATION; BLOOD STORAGE; DRUG EFFECTS; PROCEDURES; RADIATION RESPONSE; TEMPERATURE; THROMBOCYTE; THROMBOCYTE COUNT; ULTRAVIOLET RADIATION; VIRUS INACTIVATION;

BLOOD PLATELETS; BLOOD PRESERVATION; HUMANS; PLATELET COUNT; RIBOFLAVIN; TEMPERATURE; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 85007305879     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12465     Document Type: Article

References (19)

1. Goodrich RP, Gilmour D, Hovenga N, et al.: A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49:1205–1216
2. Asano H, Lee CY, Fox-Talbot K, et al.: Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84:1174–1182
3. Jackman RP, Muench MO, Heitman JW, et al.: Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice. Transfusion 2013; 53:2697–2709
4. Goodrich RP: The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000; 78(Suppl. 2):211–215
5. Mirasol Clinical Evaluation Study Group: A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50:2362–2375
6. Van der Meer PF, Cancelas JA, Cardigan R, et al.: Evaluation of overnight hold of whole blood at room temperature before component processing: effect of red blood cell (RBC) additive solutions on in vitro RBC measures. Transfusion 2011; 51(Suppl. 1):15S–24S
7. Dijkstra-Tiekstra MJ, van der Meer PF, Cardigan R, et al.: Platelet concentrates from fresh or overnight-stored blood, an international study. Transfusion 2011; 51(Suppl 1):38S–44S
8. http://www.transfusionguidelines.org.uk/transfusion-handbook/4-safe-transfusion-right-blood-right-patient-right-time-and-right-place/4-10-administration-to-the-patient. [Last accessed 25 July 2016]
9. Curvers J, De Wildt-Eggen J, Heeremans J, et al.: Flow cytometric measurement of CD62P (P-selectin) expression on platelets: a multicenter optimisation and standardization effort. Transfusion 2008; 48:1439–1446
10. Dekkers DWC, De Cuyper IM, Van der Meer PF, et al.: Influence of pH on stored human platelets. Transfusion 2007; 47:1889–1895
11. Prowse CV, de Korte D, Hess JR, et al.: Commercially available blood storage containers. Vox Sang 2014; 106:1–13
12. Sandgren P, Hild M, Sjödin A, et al.: Storage of Buffy-coat-derived platelets in additive solutions: in vitro effects on platelets prepared by the novel TACSI system and stored in plastic containers with different gas permeability. Vox Sang 2010; 99:341–347
13. Sandgren P, van Waeg G, Verheggen C, et al.: Storage of interim platelet units for 18 to 24 hours before pooling: in vitro study. Transfusion 2011; 51:1213–1219
14. Lagerberg JW, Salado-Jimena JA, Löf H, et al.: Evaluation of the quality of blood components obtained after automated separation of whole blood by a new multiunit processor. Transfusion 2013; 53:1798–1807
15. Van der Meer PF, Bontekoe IJ, Daal BB, et al.: Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution? Transfusion 2015; 55:1900–1908
16. Pietersz RN, van der Meer PF, Steneker I, et al.: Preparation of leukodepleted platelet concentrates from pooled buffy coats: prestorage filtration with Autostop BC. Vox Sang 1999; 76:231–236
17. Slichter SJ, Kaufman RM, Assmann SF, et al.: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600–613
18. Dumont LJ, Gulliksson H, van der Meer PF, et al.: Interruption of agitation of platelet concentrates: a multicenter in vitro study by the BEST Collaborative on the effects of shipping platelets. Transfusion 2007; 47:1666–1673
19. Dijkstra-Tiekstra MJ, Kuipers W, Setroikromo AC, et al.: Overnight or fresh buffy coat-derived platelet concentrates prepared with various platelet pooling systems. Transfusion 2008; 48:723–730